Valuation Northwest Biotherapeutics, Inc. Börse Stuttgart
Stocks
NBYB
US66737P6007
Biotechnology & Medical Research
|
Delayed
Börse Stuttgart
21:31:45 29/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1310 EUR | 0.00% |
|
-18.12% | -36.41% |
Company Valuation: Northwest Biotherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Market Cap 1 | 364 | 358.4 | 260.1 | - |
| Change | - | -1.53% | -27.42% | - |
| Enterprise Value (EV) 1 | 364 | 358.4 | 356.2 | 385 |
| Change | - | -1.53% | -0.61% | 8.1% |
| P/E | -3.93x | -5.72x | - | - |
| PBR | - | - | - | - |
| PEG | - | 0.1x | - | - |
| Capitalization / Revenue | - | - | - | 6.68x |
| EV / Revenue | - | - | - | 9.89x |
| EV / EBITDA | - | - | - | - |
| EV / EBIT | - | - | -5.29x | -8.12x |
| EV / FCF | - | - | -6.98x | -9.45x |
| FCF Yield | - | - | -14.3% | -10.6% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -0.07 | -0.04 | - | - |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | - | - | 38.93 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | - | -67.3 | -47.4 |
| Net income | -85.19 | -61.48 | - | - |
| Net Debt 1 | - | - | 96.08 | 124.9 |
| Reference price 2 | 0.2748 | 0.2288 | 0.1525 | 0.1525 |
| Nbr of stocks (in thousands) | 1,324,666 | 1,566,728 | 1,705,638 | - |
| Announcement Date | 3/31/25 A | 4/15/26 A | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 21.02x | 7.45x | 14.97x | 1.41% | 71.81B | ||
| 31.2x | 8.99x | 28.02x | 0.04% | 60.06B | ||
| 32.35x | 6.9x | 17.92x | -.--% | 27.93B | ||
| -72.02x | 13.86x | -70.68x | -.--% | 25.7B | ||
| -15.29x | 5.82x | -7.32x | -.--% | 24.89B | ||
| 28.77x | 5.41x | 17.98x | -.--% | 20.92B | ||
| 42.74x | 15.97x | 32.4x | 0.35% | 15.04B | ||
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | ||
| 990.12x | 34.59x | 597.44x | -.--% | 13.87B | ||
| Average | 119.66x | 11.60x | 71.48x | 0.2% | 30.52B | |
| Weighted average by Cap. | 62.96x | 9.76x | 38.56x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWBO Stock
- NBYB Stock
- Valuation Northwest Biotherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















